Discovery of Selective Inhibitors for In Vitro and In Vivo Interrogation of Skeletal Myosin II

Citations Over TimeTop 23% of 2021 papers

Abstract

Myosin IIs, actin-based motors that utilize the chemical energy of adenosine 5'-triphosphate (ATP) to generate force, have potential as therapeutic targets. Their heavy chains differentiate the family into muscle (skeletal [SkMII], cardiac, smooth) and nonmuscle myosin IIs. Despite the therapeutic potential for muscle disorders, SkMII-specific inhibitors have not been reported and characterized. Here, we present the discovery, synthesis, and characterization of "skeletostatins," novel derivatives of the pan-myosin II inhibitor blebbistatin, with selectivity 40- to 170-fold for SkMII over all other myosin II family members. In addition, the skeletostatins bear improved potency, solubility, and photostability, without cytotoxicity. Based on its optimal in vitro profile, MT-134's in vivo tolerability, efficacy, and pharmacokinetics were determined. MT-134 was well-tolerated in mice, impaired motor performance, and had excellent exposure in muscles. Skeletostatins are useful probes for basic research and a strong starting point for drug development.

Related Papers

• → Non-muscle myosin II induces disassembly of actin stress fibres independently of myosin light chain dephosphorylation(2011)47 cited
• → The molecular basis of thin filament activation: from single molecule to muscle(2017)34 cited
• → Measurement of enzymatic and motile activities of Arabidopsis myosins by using Arabidopsis actins(2017)11 cited
• → In vitro movements of actin and myosin filaments from muscle(1986)6 cited
• → IMPORTANCE OF CONTRACTILE PROTEIN MEASUREMENT IN THE DILATED URETER(1986)